Editor’s note: Addition to February 17’s Daily Alert on OncoGenex Pharmaceuticals (OGXI)
Editor Vivian Lewis asked that I add an important note: Teva Pharma, the Israeli generics giant looking for a new mission in life, has financed the phase III trials of OncoGenix custirsen starting with certain resistant prostate cancers. Geroge Soros has just bought 4% of Teva. Teva may offer an alternative opportunity to participate in the potential of OGXI.